These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29558031)

  • 1. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases.
    Krela-Kaźmierczak I; Szymczak-Tomczak A; Łykowska-Szuber L; Wysocka E; Michalak M; Stawczyk-Eder K; Waszak K; Linke K; Eder P
    Adv Clin Exp Med; 2018 Apr; 27(4):449-453. PubMed ID: 29558031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density and bone metabolism in patients with inflammatory bowel disease.
    Shirazi KM; Somi MH; Rezaeifar P; Fattahi I; Khoshbaten M; Ahmadzadeh M
    Saudi J Gastroenterol; 2012; 18(4):241-7. PubMed ID: 22824766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
    Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
    Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
    Bernstein CN; Sargent M; Leslie WD
    Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis.
    Stanisławowski M; Wiśniewski P; Guzek M; Wierzbicki PM; Adrych K; Smoczyński M; Sworczak K; Celiński K; Kmieć Z
    J Crohns Colitis; 2014 Aug; 8(8):802-10. PubMed ID: 24439762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
    Kim HR; Lee SH; Kim HY
    Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region.
    Krela-Kaźmierczak I; Michalak M; Szymczak-Tomczak A; Łykowska-Szuber L; Stawczyk-Eder K; Waszak K; Kucharski MA; Dobrowolska A; Eder P
    Pol Arch Intern Med; 2018 Aug; 128(7-8):447-454. PubMed ID: 30057387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
    Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
    Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
    J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor (VDR) TaqI polymorphism, vitamin D and bone mineral density in patients with inflammatory bowel diseases.
    Szymczak-Tomczak A; Krela-Kaźmierczak I; Kaczmarek-Ryś M; Hryhorowicz S; Stawczyk-Eder K; Szalata M; Skrzypczak-Zielińska M; Łykowska-Szuber L; Eder P; Michalak M; Dobrowolska A; Słomski R
    Adv Clin Exp Med; 2019 Jul; 28(7):955-960. PubMed ID: 30929318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
    Moschen AR; Kaser A; Enrich B; Ludwiczek O; Gabriel M; Obrist P; Wolf AM; Tilg H
    Gut; 2005 Apr; 54(4):479-87. PubMed ID: 15753532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
    Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
    Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease.
    Tan B; Li P; Lv H; Li Y; Wang O; Xing XP; Qian JM
    J Dig Dis; 2014 Mar; 15(3):116-23. PubMed ID: 24354597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated bone mineral density status in Saudi patients with inflammatory bowel disease.
    Ewid M; Al Mutiri N; Al Omar K; Shamsan AN; Rathore AA; Saquib N; Salaas A; Al Sarraj O; Nasri Y; Attal A; Tawfiq A; Sherif H
    World J Gastroenterol; 2020 Sep; 26(35):5343-5353. PubMed ID: 32994692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Femoral neck osteopenia in patients with inflammatory bowel disease.
    Pollak RD; Karmeli F; Eliakim R; Ackerman Z; Tabb K; Rachmilewitz D
    Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
    Jahnsen J; Falch JA; Mowinckel P; Aadland E
    Scand J Gastroenterol; 2004 Feb; 39(2):145-53. PubMed ID: 15000276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density in Iranian patients with inflammatory bowel disease.
    Zali M; Bahari A; Firouzi F; Daryani NE; Aghazadeh R; Emam MM; Rezaie A; Shalmani HM; Naderi N; Maleki B; Sayyah A; Bashashati M; Jazayeri H; Zand S
    Int J Colorectal Dis; 2006 Dec; 21(8):758-66. PubMed ID: 16463035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.